Related Experiment Video

Updated: Sep 23, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Levels of non-high density lipoprotein cholesterol (non-HDL-C) in patients with ischaemic heart disease

Shoaib Tauheed1, Shaheen Shoaib, M Naeem ul Haque

  • 1Dow Medical College, Karachi, Pakistan. shaheens@cyber.net.pk

Journal of Ayub Medical College, Abbottabad : JAMC
|July 23, 2003
PubMed

Insights

Non-high-density lipoprotein cholesterol (non-HDL-C) levels were significantly higher in patients with ischaemic heart disease (IHD) compared to controls. This suggests non-HDL-C is a potential indicator for IHD risk.

Area of Science:

  • Cardiology
  • Lipid Metabolism
  • Atherosclerosis

Background:

  • Ischaemic heart disease (IHD) is linked to abnormal lipid profiles, including high cholesterol, LDL-C, triglycerides, and low HDL-C.
  • Non-high-density lipoprotein cholesterol (non-HDL-C), calculated as total cholesterol minus HDL-C, is emerging as a significant factor in IHD.
  • Elevated non-HDL-C may indicate increased risk for cardiovascular events.

Purpose of the Study:

  • To investigate the association between non-HDL-C levels and IHD.
  • To determine if non-HDL-C is elevated in patients diagnosed with IHD.

Main Methods:

  • A cross-sectional study comparing 30 male IHD patients (average age 50) with 30 male controls (average age 47.27).
  • Fasting blood samples were analyzed for serum cholesterol and HDL levels using an autoanalyzer.
  • Non-HDL-C was calculated from total cholesterol and HDL-C measurements.

Main Results:

  • Non-HDL-C levels were significantly higher in the IHD patient group (158.00 +/- 4.79) compared to the control group (127.63 +/- 2.82).
  • The difference in non-HDL-C between patients and controls was statistically significant (p < 0.001).

Conclusions:

  • Non-HDL-C encompasses atherogenic lipid particles like LDL-C and VLDL remnants, indicating its role in IHD.
  • This study supports non-HDL-C as a potential emerging coronary risk factor.
  • Non-HDL-C may serve as a cost-effective screening test for inclusion in coronary risk assessments.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...